Brightpath Biotherapeutics submitted an IND application to the FDA to start a Phase I trial of BP-2202 in the U.S. The trial is registered as NCT07667868, marking the program’s regulatory step into clinical testing. BP-2202 is targeting multiple myeloma, adding to the growing set of early-stage therapies being initiated through IND pathways as developers position assets for Phase 1 dose-finding and safety readouts in the U.S. market.